Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Various peptide therapeutics are utilized as replacement therapies, in order to supplement peptide hormones, when endogenous levels are inadequate or absent. Insulin and adrenocorticotrophic hormone (ACTH) are peptides that are isolated from natural sources, whereas oxytocin and vasopressin are synthetic peptides.
The global peptide therapeutics market is estimated to be valued at US$ 23,319.3 Mn in 2019, in terms of value, and is expected to surpass US$ 57,166.5 Mn by 2027.
Global Peptide Therapeutics Market: Drivers
The increasing adoption of peptide therapeutics is the factor that is expected to drive growth of the global peptide therapeutics market over the forecast period. Moreover, peptide therapeutics are manufactured with lower rate of production complexity, in comparison to protein-based-biopharmaceuticals. This results in lower production costs, which further drives adoption of peptides therapeutics over small molecules and biopharmaceuticals.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1837
Global Peptide Therapeutics Market: Opportunities
Rising development of multifunctional peptides and conjugates are expected to offer lucrative growth opportunities for players in the market. For instance, in February 2019, researchers from University of Milan reported that the polypeptide lunasin derived from bioactive food offered hypocholesterolemic, antioxidant, and anti-inflammatory properties, which can be effective in preventing cardiovascular diseases.
Global Peptide Therapeutics Market: Restraints
However, therapeutic peptides have low membrane permeability and are prone to hydrolysis and oxidation, and these factors are expected to hamper growth of the market over the forecast period.
Among product type, branded segment in global peptide therapeutics market was valued at US$ 12,415.2 Mn in 2018 and is expected to reach US$ 27,349.8 Mn by 2027 exhibiting a CAGR of 9.1% during the forecast period. Moreover, branded medications have extensive patent protections and highly preferred by the physicians in developed as well as emerging economies. However, branded medications are costly compared to generic peptide therapeutics.
Among application, cancer segment held dominant position in the market in 2018, accounting for 34.3% market share, in terms of value, followed by metabolic disorders and central nervous system disorders segments, respectively.
The increasing prevalence of cancer is expected to offer lucrative growth opportunities for manufacturers in the market. For instance, according to the National Cancer Institute, 2016, the number of new cancer cases, each year is expected to increase to 23.6 million by 2030, globally.
Among route of administration, parenteral segment held accounted for largest market share in 2018, accounting for 70.4% share in terms of value, followed by transdermal route and mucosal route segments respectively. Several parenteral peptide therapeutics are launched in the market by market players. These drugs are effective as the drug is directly administered in the blood stream bypassing gastrointestinal tract.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1837
The increasing adoption of peptide therapeutics for the treatment of cancer, is expected to drive the market growth over the forecast period. For instance, in January 2020, IBicycle Therapeutics plc., a biotechnology company that develops therapeutics based on its proprietary bicyclic peptide technology entered into a collaboration with Cancer Research UK for funding in R&D of BT7401, a multivalent Bicycle CD137 agonist indicated for the treatment of cancer.
Moreover, major players in the market are focusing on collaborations with universities for R&D of new peptide therapeutics. For instance, in 2018, Sapience Therapeutics, Inc., a biotechnology company focused on R&D in peptide therapeutics, entered into a collaboration with University of Bath to discover new therapeutic agents.
- The medicines regulatory authorities of the Member States, or ‘National Competent Authorities’, are responsible for the authorization of medicines available in the EU that do not pass though the centralized procedure.
- For clinical trials, European Medicines Agency maintains only EUDRACT and EUDRAVigilance database. The National agency of each country is responsible for conducting the trial.
- CHMP or Committee for Medicinal Products for Human use assess the product for marketing approval in EU
- In EU, biologic is wide umbrella term that includes peptides
- Non-clinical studies are carried out according to ICH-S6 guidelines
- There is a centralized MAA procedure; however, biologics are also approved at member state level
Browse Press Release: https://bit.ly/33i5E7t
Global Peptide Therapeutics Market: Competitive Landscape
Key players operating in the global peptide therapeutics market include AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.
Global Peptide Therapeutics Market: Key Developments
January 2020: Cybrexa Therapeutics, a privately-held biotechnology company focuses on developing next-generation tumor-targeted cancer therapies, announced CBX-12 (alphalex exatecan) as the new lead development program. The Cybrexa alphalex technology platform consists of a pHLIP peptide, linker, and small molecule anti-cancer agent.
January 2020: Protagonist Therapeutics, Inc. announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc., for co-development and commercialization of PTG-200, an oral, gut-restricted IL-23 receptor antagonist and second generation peptides for the treatment of inflammatory bowel disease.
Request A FREE Sample Copy – Peptide Therapeutics Market Report Click here: https://www.coherentmarketinsights.com/insight/request-sample/1837
- By Product Type
- By Application
- Central Nervous Systems
- Metabolic Disorders
- Hematological Disorders
- Gastrointestinal Disorders
- Respiratory Disorders
- Other Applications
- By Route of Administration
- Parenteral Route
- Mucosal Route
- Oral Route
- Transdermal Route
- By Region
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027